Amarin reports Q1 adjusted EPS 2c, consensus (3c)

Reports Q1 revenue $84.654M, consensus $81.23M. "I am truly honored to lead Amarin during this time of transition," said 4Aaron Berg, Amarin’s Interim President and CEO. Berg continued, "Amarin’s first quarter performance was marked by solid revenue generation in the U.S. and a stable cash position. However, we are not where we need to be in Europe. While we will continue to work to optimally manage the U.S. business, I am focused with the team on ways to accelerate patient access and revenue in Europe. Amarin’s objectives remain to bring the benefits of VASCEPA(R)/VAZKEPA(R) to patients around the globe and to maximize value for shareholders."